The case for & against
Bull & Bear analysis
Codexis, Inc. (NASDAQ: CDXS) is a biotech company that specializes in biocatalytic enzymes and innovative manufacturing solutions aimed primarily at the RNA medicine market. Positioned within a growing industry due to the increasing demand for siRNA therapeutic production, Codexis is at the forefront of leveraging its Ecosynthesis platform to meet production needs while enhancing environmental sustainability. The company is currently transitioning from traditional enzyme production to a focus on oligonucleotide technology, highlighting its adaptive strategy in a rapidly evolving market.
Bull says
- ↑Q1 2026 revenues $15.2M (+102.7% YoY) driven by Merck agreement
- ↑Product gross margin rose to 71% in Q1 from 55% last year
- ↑New GMP facility on track to support half-kg siRNA scale by late 2027
- ↑Identified 50+ Ecosynthesis opportunities across 40 companies
- ↑2026 revenue guidance at $72–76M, with >50% weighted to H2
- ↑Strong analyst revisions sentiment and solid liquidity suggest undervaluation
Bear says
- ↓Q1 net loss narrowed to $8.7M vs $20.7M prior year, profitability elusive
- ↓Order timing variability poses revenue and cash-flow forecasting risks
- ↓Scaling Ecosynthesis from 100g to 500g faces development hurdles
- ↓siRNA production adoption may lag, delaying expected volume growth
- ↓Delays in scaling could jeopardize key partnerships and hamper pipeline
- ↓Weak profitability metrics and low institutional interest raise financial concerns
Investment themes with CDXS
Genetic and drug innovations driving medical breakthroughs
Drug development driving global healthcare solutions
Stocks with highest short interest
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- Total revenues were $15.2 million for the first quarter of 2026 compared to $7.5 million in the first quarter of 2025. The increase was primarily due to revenue from the Merck Technology Transfer Agreement executed in the fourth quarter of 2025, which has now been fully recognized.
- Product gross margin was 71% for the first quarter of 2026, which compares to 55% for the first quarter of 2025. For the first quarter of 2026, the increase was primarily driven by product mix and sales declines in several low-margin products that were replaced with more profitable product sales.
- We reiterate our revenue guidance and expect 2026 revenue in the range of $72 million to $76 million. Like the quarterly trends we saw last year, we expect 2026 revenue to be more heavily weighted towards the second half of 2026 versus the first half.
Bear points
- Net loss for the first quarter of 2026 was 8.7 million compared to the loss of 20.7 million for the first quarter of 2025.
- We don't have unlimited bandwidth. And actually, just right at the moment, we are working on improving productivity and throughput so that we can make sure that we have the right kind of velocity and capacity to meet those customers' demands.
- The net loss for the first quarter of 2026 was $8.7 million compared to the loss of $20.7 million for the first quarter of 2025, indicating ongoing financial challenges.